Biocept Inc. (BIOCQ)
| Market Cap | 43.53K |
| Revenue (ttm) | 1.36M |
| Net Income (ttm) | -30.61M |
| Shares Out | 1.04M |
| EPS (ttm) | -50.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,169 |
| Open | 0.0400 |
| Previous Close | 0.0400 |
| Day's Range | 0.0400 - 0.0650 |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BIOCQ
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications... [Read more]
Financial Performance
In 2022, Biocept's revenue was $25.86 million, a decrease of -57.78% compared to the previous year's $61.25 million. Losses were -$32.09 million, 1036.2% more than in 2021.
Financial StatementsNews
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with bre...
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing a...
Biocept to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that management will particip...
Biocept to Hold Business Update Conference Call on August 30, 2023
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business u...
Biocept Reports Second Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30...
Biocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, announces that its CNSid...
Biocept Announces the Passing of Board Chair M. Faye Wilson
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”) announces that M. Faye Wilson, Board Chair, passed away unexpectedly on Monday, July 10. The Board ...
Biocept Names Antonino Morales as President and Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CSF--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and services, has named Antonino Moral...
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present a...
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide™ Versus Cytology
SAN DIEGO--(BUSINESS WIRE)---- $BIOC #CNSide--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces a poster pre...
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces the pricing of an underwritten...
Biocept Announces One-for-Thirty Reverse Stock Split
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that ...
Biocept Reports First Quarter 2023 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 ...
Biocept Reports 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 ...
Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide™ to Evaluate Patients with Leptomeningeal Metastases
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical tr...
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purc...
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (NasdaqCM: BIOC) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has en...
Biocept Reports Third Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended Sept...
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Dir...
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investiga...
Biocept Reports Second Quarter 2022 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June ...
Biocept to Present at the LD Micro Main Event XV
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV...
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patien...
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held today, October 14 at 1 p.m...
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held October 14 at 1 p.m. Easte...